Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?

References

• Garbutt M, Liebscher R, Wahl-Jensen V, et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol. 2004;78(10):5458–5465.
   PubMed Web of Science ®Google Scholar
• Jones SM, Feldmann H, Stroher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med. 2005;11(7):786–790.
   PubMed Web of Science ®Google Scholar
• Qiu X, Fernando L, Alimonti JB, et al. Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PLoS One. 2009;4(5):e5547.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Daddario-Dicaprio KM, Lewis MG, et al. Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog. 2008;4(11):e1000225.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Geisbert JB, Leung A, et al. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol. 2009;83(14):7296–7304.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Feldmann H. Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis. 2011;204(Suppl 3):S1075–S1081.
   PubMed Web of Science ®Google Scholar
• Mire CE, Miller AD, Carville A, et al. Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl Trop Dis. 2012;6(3):e1567.
   PubMed Web of Science ®Google Scholar
• Jones SM, Stroher U, Fernando L, et al. Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. J Infect Dis. 2007;196(Suppl 2):S404–S412.
   PubMedGoogle Scholar
• Plotkin SA. Zika as still another argument for a new path to vaccine development. Clin Microbiol Infect. 2016;22(4):294–295.
   PubMed Web of Science ®Google Scholar
• Agnandji ST, Huttner A, Zinser ME, et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe. N Engl J Med. 2016;374(17):1647–1660.
   PubMed Web of Science ®Google Scholar
• Huttner A, Dayer JA, Yerly S, et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis. 2015;15(10):1156–1166.
   PubMed Web of Science ®Google Scholar
• Agnandji ST, Fernandes JF, Bache EB, et al. Safety and immunogenicity of rVSVDeltaG-ZEBOV-GP Ebola vaccine in adults and children in Lambarene, Gabon: A phase I randomised trial. PLoS Med. 2017;14(10):e1002402.
   PubMed Web of Science ®Google Scholar
• Regules JA, Beigel JH, Paolino KM, et al. A recombinant vesicular stomatitis virus Ebola vaccine. N Engl J Med. 2017;376(4):330–341.
   PubMed Web of Science ®Google Scholar
• ElSherif MS, Brown C, MacKinnon-Cameron D, et al. Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial. Cmaj. 2017;189(24):E819–E27.
   PubMed Web of Science ®Google Scholar
• Henao-Restrepo AM, Camacho A, Longini IM, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!). Lancet. 2017;389(10068):505–518.
   PubMed Web of Science ®Google Scholar
• Kennedy SB, Bolay F, Kieh M, et al. Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in Liberia. N Engl J Med. 2017;377(15):1438–1447.
   PubMed Web of Science ®Google Scholar
• Samai M, Seward JF, Goldstein ST, et al. The Sierra Leone trial to introduce a vaccine against Ebola: an evaluation of rVSVG-ZEBOV-GP vaccine tolerability and safety during the West Africa Ebola outbreak. J Infect Dis. 2018;217(suppl_1):S6–S15.
   PubMedGoogle Scholar
• Soka MJ, Choi MJ, Baller A, et al. Prevention of sexual transmission of Ebola in Liberia through a national semen testing and counselling programme for survivors: an analysis of Ebola virus RNA results and behavioural data. Lancet Glob Health. 2016;4(10):e736–e743.
   PubMed Web of Science ®Google Scholar
• Jacobs M, Rodger A, Bell DJ, et al. Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet. 2016;388(10043):498–503.
   PubMed Web of Science ®Google Scholar
• Medaglini D, Santoro F, Siegrist CA. Correlates of vaccine-induced protective immunity against Ebola virus disease. Semin Immunol. 2018. doi: 10.1016/j.smim.2018.07.003. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Martin JE, Graham BS, et al. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol. 2009;7(5):393–400.
   PubMed Web of Science ®Google Scholar
• Marzi A, Engelmann F, Feldmann F, et al. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci U S A. 2013;110(5):1893–1898.
   PubMed Web of Science ®Google Scholar
• Farooq F, Beck K, Paolino KM, et al. Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine. Sci Rep. 2016;6:27944.
   PubMed Web of Science ®Google Scholar
• Rechtien A, Richert L, Lorenzo H, et al. Systems vaccinology identifies an early innate immune signature as a correlate of antibody responses to the Ebola vaccine rVSV-ZEBOV. Cell Rep. 2017;20(9):2251–2261.
   PubMed Web of Science ®Google Scholar
• Menicucci AR, Sureshchandra S, Marzi A, et al. Transcriptomic analysis reveals a previously unknown role for CD8(+) T-cells in rVSV-EBOV mediated protection. Sci Rep. 2017;7(1):919.
   PubMedGoogle Scholar
• Dye JM, Herbert AS, Kuehne AI, et al. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci U S A. 2012;109(13):5034–5039.
   PubMed Web of Science ®Google Scholar
• Mendoza EJ, Racine T, Kobinger GP. The ongoing evolution of antibody-based treatments for Ebola virus infection. Immunotherapy. 2017;9(5):435–450.
   PubMed Web of Science ®Google Scholar
• Group PIW, Multi-National PIIST, Davey RT Jr., Dodd L, Proschan MA, et al. A randomized, controlled trial of ZMapp for Ebola virus infection. N Engl J Med 2016;375(15):1448–1456.
   PubMed Web of Science ®Google Scholar
• Khurana S, Fuentes S, Em C, et al. Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies. Nat Med. 2016;22(12):1439–1447.
   PubMed Web of Science ®Google Scholar
• Wilkinson DE, Page M, Mattiuzzo G, et al. Comparison of platform technologies for assaying antibody to Ebola virus. Vaccine. 2017;35(9):1347–1352.
   PubMed Web of Science ®Google Scholar
• Huttner A, Combescure C, Grillet S, et al. A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa. Sci Transl Med. 2017; 9(385)
   PubMed Web of Science ®Google Scholar
• Dahlke C, Kasonta R, Lunemann S, et al. Dose-dependent T-cell dynamics and cytokine cascade following rVSV-ZEBOV immunization. EBioMedicine. 2017;19:107–118.
   PubMed Web of Science ®Google Scholar
• Huttner A, Agnandji ST, Combescure C, et al. Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study. Lancet Infect Dis. 2018;18(7):738–748.
   PubMed Web of Science ®Google Scholar
• Heppner DG Jr., Kemp TL, Martin BK, et al. Safety and immunogenicity of the rVSVG-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study. Lancet Infect Dis. 2017;7(8):854–866.
   PubMedGoogle Scholar
• De Santis O, Audran R, Pothin E, et al. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect Dis. 2016;16(3):311–320.
   PubMed Web of Science ®Google Scholar
• Ewer K, Rampling T, Venkatraman N, et al. A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA. N Engl J Med. 2016;374(17):1635–1646.
   PubMed Web of Science ®Google Scholar
• Tapia MD, Sow SO, Lyke KE, et al. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2016;16(1):31–42.
   PubMed Web of Science ®Google Scholar